SOURCE: Nu-Med Plus, Inc.

Nu-Med Plus, Inc.

June 23, 2015 08:00 ET

Nu-Med Plus Contacts World Health Organization in Regards to MERS Epidemic and Global Threat

SALT LAKE CITY, UT--(Marketwired - Jun 23, 2015) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announced one of its medical doctors has contacted the World Health Organization and offered assistance in regards to cost effective prevention and treatment of the MERS virus with Inhaled Nitric Oxide.

MERS is an illness caused by a virus (more specifically, a coronavirus) called Middle East Respiratory Syndrome. MERS affects the respiratory system (lungs and breathing tubes) and patients develop a severe acute respiratory illness with symptoms of fever, cough and shortness of breath. Its mortality rate has exceeded 30%.

Doctor Brett J. Earl MD, NU-Med Plus Vice President and Board Member, stated: "Extensive and deliberate research has been compiled in regards to Nitric Oxide and its efficacy and lethality towards Coronaviruses. MERS is a subset of the family of Coronaviruses."

Doctor Earl notes, "SARS, another subset of Coronavirus, with significant mortality has already been shown to be susceptible to Inhaled Nitric Oxide. This confirmation suggests that all Coronavirus are vulnerable to Inhaled Nitric Oxide. There is no reason to believe that the MERS Coronavirus would show less efficacy."

Jeff Robins, President and CEO of Nu-Med Plus, Inc., remarked, "After watching the spread of MERS from the Middle East to Korea and China, and realizing it potential global impact we feel compelled to offer our unique technology to those who need it most."

About Nu-Med Plus, Inc.

Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use. For more company information please visit www.nu-medplus.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Contact Information

  • Contact:
    Jeff Robins
    President
    801-746-3570